The cAMP-regulated phosphoprotein 19 (ARPP-19) plays a key role in cell mitotic G2/M transition. Expression of ARPP-19 was increased in human hepatocellular carcinoma (HCC) compared to adjacent non-tumorous liver tissues in 36 paired liver samples, and the level of ARPP-19 in HCC tissues was positively correlated with the tumor size. To determine the interrelationship between ARPP-19 expression and HCC, we silenced ARPP-19 expression in the human hepatocarcinoma HepG2 and SMMC-7721 cells using lentivirus encoding ARPP-19 siRNA. HepG2 and SMMC-7721 cells with ARPP-19 knockdown displayed lowered cell growth rate, retarded colony formation and increased arrest at the G2/M phase transition. Silencing ARPP-19 in HCC cells resulted in decreased protein levels of phospho-(Ser) CDKs substrates and increased levels of inactivated cyclin division cycle 2 (Cdc2). Therefore, ARPP-19 may play a role in HCC pathogenesis through regulating cell proliferation.
Protein arginine methyltransferase 1 (PRMT1) serves as a critical epigenetic modulator involved in a wide range of physiological and pathological processes. Previous studies have established its fundamental roles in essential cellular mechanisms such as DNA repair, transcriptional regulation, and signal transduction. Dysregulation of PRMT1 has been further associated with the pathogenesis of various diseases, including cancer, metabolic disorders, and immune dysfunction. However, a systematic synthesis of the multifaceted functions of PRMT1 across these diverse pathological contexts remains lacking. This review seeks to address this gap by comprehensively examining the molecular mechanisms, biological functions, and context‐dependent roles of PRMT1. We integrate recent advances spanning multiple disease domains, with a particular focus on cancer, chronic liver diseases, cardiovascular disorders, neurodegenerative conditions, and immune‐related pathologies. In addition, we elucidate the mechanistic links between PRMT1 dysregulation and disease pathogenesis. Further, the development and clinical potential of small‐molecule inhibitors are also summarized. This review offers new perspectives on PRMT1‐related disease mechanisms and lays a theoretical foundation for the development of targeted therapies. Ultimately, this review aims to contribute to the progression of precision medicine and the enhancement of global health outcomes.
15 March 2005 in Journal of Chinese Integrative Medicine
Aquaporins (AQPs) represent a class of integral membrane proteins that function as selective water channels, facilitating the transit of water molecules across biological membranes. Under specific conditions, these proteins may also mediate the permeation of small solutes, including glycerol, hydrogen peroxide, urea, carbon dioxide, and ammonia. Investigations into AQPs have unveiled distinctive structural attributes and functional properties. Evidence indicates that AQPs are broadly distributed across diverse tissues and organ systems in humans, contributing to essential physiological processes. An expanding body of literature highlights the involvement of AQPs in disease pathogenesis and progression, particularly in cellular behaviors such as proliferation and motility, pulmonary gas exchange, and the modulation of non-canonical signaling pathways. This review comprehensively outlines the tissue-specific and subcellular distribution profiles, physiological roles, and regulatory mechanisms associated with AQPs. It further characterizes the alterations in AQP functionality under pathological states, delineates their involvement and mechanistic contributions to multisystem disorders, and provides an overview of therapeutic strategies targeting AQPs, along with their translational prospects. In addition, key gaps in current knowledge are identified, and pivotal research directions, such as tissue-specific modulation and the design of targeted inhibitors and activators, are proposed to advance the translational application of AQPs as diagnostic and therapeutic targets.